E-DRUG Archives (by date)

• Thread Index

April 30, 2002
• [e-drug] Re: Uganda MOH website
  • From: Bonnie Fundafunda <bfunda@echohealth.org.uk>
• [e-drug] Re: amodiaquine
  • From: Marcus Reidenberg <mmreid@med.cornell.edu>
• [e-drug] Announcing the new E-Drug website
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Re: Internet sales threaten drug companies' supremacy
  • From: Eduardo Satué <fsxxi@recol.es>
• [e-drug] Re: Independence of pharmacy inspection
  • From: Ayesha Ahmed <helpline@thenetwork.org.pk>
• [e-drug] Global funding for malaria. How much for Africa?
  • From: FH Jansen <fhjansen@skynet.be>
• [e-drug] Re: Toxicity amodiaquine vs ARVs
  • From: Kibumba George <kibumba@yahoo.com>
• [e-drug] Re: Essential antimalarials for paediatric use
  • From: FH Jansen <fhjansen@skynet.be>
• [e-drug] Uganda MOH website
  • From: "Peggy D'Adamo" <mdadamo@welchlink.welch.jhu.edu>
April 27, 2002
• [e-drug] Re: WHO on artemisine combination therapy
  • From: Mary Ojoo <mojoo@gerties.org>
• [e-drug] Designing medicines information and labels
  • From: WilbertBannenberg@compuserve.com
April 26, 2002
• [e-drug] Meeting Report TA, Doha, TRIPS and Health
  • From: Mai DO <MDO@paris.msf.org>
• [e-drug] Re: Amodiaquine
  • From: Richard Laing <richardl@bu.edu>
• [e-drug] Global Fund: Activists demand focus on AIDS treatment
  • From: Olivier Jablonski <ojablonski@free.fr>
• [e-drug] WHO on artemisine combination therapy
  • From: WilbertBannenberg@compuserve.com
• [e-drug] Ethics of research on healthcare in developing countries
  • From: Yvonne Melia <ymelia@nuffieldfoundation.org>
• [e-drug] Medicines in Europe Forum
  • From: Christophe Kopp <Christophe.Kopp@wanadoo.fr>
• [e-drug] Internet sales threaten drug companies' supremacy
  • From: E-drug <e-drug@usa.healthnet.org>
April 25, 2002
• [e-drug] Global Fund commits USD 616m
  • From: e-drug@usa.healthnet.org
• [e-drug] Re: ISDB on EU consultation on child medicines
  • From: Mary Ojoo <mojoo@gerties.org>
• [e-drug] US Congress certain to approve major GFATM boost
  • From: Paul Davis <pdavis@critpath.org>
April 24, 2002
• [e-drug] New WHO ARV guidelines
  • From: Jos Perriens <perriensj@who.ch>
• [e-drug] Re: Safe disposal of expired drugs
  • From: Robin Gray <grayr@who.ch>
• [e-drug] ISDB on EU consultation on child medicines
  • From: Christophe Kopp <Christophe.Kopp@wanadoo.fr>
• [e-drug] Deregulation of the pharmaceutical sector in Pakistan
  • From: Azhar Hussain <azhar@thenetwork.org.pk>
• [e-drug] detailed communication re new WHO EDL
  • From: andy@healthlink.org.za
• [e-drug] new WHO ART guidelines
  • From: Vareldzisb@who.int
April 23, 2002
• [e-drug] Safe disposal of expired drugs
  • From: Jan Komrska <komrska@yubc.net>
April 22, 2002
• [e-drug] WHO new EDL to contain 10 ARVs
  • From: WilbertBannenberg@compuserve.com
• [e-drug] WHO Press Release on ARVs and the Essential Drugs List
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] HGAP/MSF/NGO Global Fund Press Call
  • From: Asia.Russell, <asia@critpath.org>
April 19, 2002
• [e-drug] SA U turn on AIDS Policy!!
  • From: "Ellen 't Hoen" <ehoen@paris.msf.org>
• [e-drug] Help - drug regulation
  • From: Khalil Elouardighi <gerrold@noos.fr>
• [e-drug] NEJM -- Ross et al. 346(16):1212, 2002.
  • From: Valeria Frighi <valeria.frighi@dtu.ox.ac.uk>
• [e-drug] Re: MSF letters Lancet, Generic medicines & Global Fund
  • From: Kibumba George <kibumba@yahoo.com>
April 18, 2002
• [e-drug] Oxfam on international trade rules
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] MSF Letter to Global Fund Board and TRP
  • From: Rachel Cohen <Rachel_COHEN@msf.org>
• [e-drug] SEAM Program country initiatives
  • From: Keith Johnson <kjohnson@msh.org>
April 17, 2002
• [e-drug] Re: Independence of pharmacy inspection
  • From: Subhash Mandal <pharmid@vsnl.net>
• [e-drug] New guidelines available
  • From: Enid Meldrum <emeldrum@tg.com.au>
April 16, 2002
• [e-drug] Free Online Access to Academic Journals
  • From: Sharron Lawrence <sharron.lawrence@tandf.co.uk>
• [e-drug] Re: Independence of pharmacy inspection
  • From: Duangtip <Duangtip.Hongsamoot@lshtm.ac.uk>
April 15, 2002
• [e-drug] Re: Study on tax subsidies for donations of expiring drugs
  • From: James Russo <JBRusso@aol.com>
• [e-drug] Re: Independence of pharmacy inspection
  • From: Raj Vaidya <pharmhin@goatelecom.com>
• [e-drug] Vitamin A and child deaths in India
  • From: Uzodinma Adirieje <afrepton@hotmail.com>
• [e-drug] ARV-treatment in developing countries?
  • From: Stine Nielsen <stinen@mdb.ku.dk>
• [e-drug] European socialist on TRIPs and Public Health
  • From: Seco Gerard <Seco_GERARD@msf.org>
• [e-drug] Re: TheNetwork's Campaign Against GST on medicines
  • From: Azhar Hussain <azhar@thenetwork.org.pk>
April 14, 2002
• [e-drug] Re: Standardized Pill Imprint Codes USP
  • From: Stein Lyftingsmo <lyftings@online.no>
• [e-drug] Re: Independence of pharmacy inspection
  • From: Jon Harper <jrharper@axelero.hu>
• [e-drug] Independence of pharmacy inspection
  • From: Duangtip <Duangtip.Hongsamoot@lshtm.ac.uk>
• [e-drug] Re: Thalidomide supplier
  • From: FH Jansen <fhjansen@skynet.be>
April 12, 2002
• [e-drug] Re: TheNetwork's Campaign Against GST on medicines
  • From: Warren Kaplan <wak22@attbi.com>
• [e-drug] Involve key players at implementation stage
  • From: Kibumba George <kibumba@yahoo.com>
• [e-drug] MSF letter Lancet: Generic medicines are not substandard
  • From: Ingrid Cox <Ingrid_COX@msf.org>
• [e-drug] Re: Study on tax subsidies for donations of expiring drugs
  • From: Americo Focesi Pelicioni <americofp@uol.com.br>
• [e-drug] Article in Milwaukee Journal Sentinel
  • From: Cathy Crawford <crawfordcathy@hotmail.com>
• [e-drug] Brain drain of health professionals (cont'd)
  • From: Susan Foster <sfoster@bu.edu>
• [e-drug] Re: Study on tax subsidies for donations of expiring drugs
  • From: Carolyn Green <greencm@dial.pipex.com>
• [e-drug] TheNetwork's Campaign Against GST on medicines
  • From: Azhar Hussain <azhar@thenetwork.org.pk>
• [e-drug] Re: Double or dubious standards for regulation and export?
  • From: Ayesha Ahmed <helpline@thenetwork.org.pk>
• [e-drug] Re: What drugs could be removed from WHO Model EDL?
  • From: Ayesha Ahmed <helpline@thenetwork.org.pk>
• [e-drug] RE: Study on tax subsidies for donations of expiring drugs
  • From: "Jeffrey W. Mecaskey" <limbu@bellatlantic.net>
• [e-drug] More information on DTCA
  • From: Lisa Hayes <Lisa@hai.antenna.nl>
• [e-drug] Re: Double or dubious standards for regulation and export?
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] Re: Proposed Donation Legislation in the UK
  • From: Joel Lexchin <joel.lexchin@utoronto.ca>
• [e-drug] Re: Standardized pill imprint codes USP
  • From: Gordon Schiff <Gdschiff@aol.com>
• [e-drug] Australian Prescriber April 2002
  • From: Susan Reid <sreid@nps.org.au>
April 11, 2002
• [e-drug] Recruitment of patients for drug trials
  • From: Cheri Grace <CGrace@london.edu>
• [e-drug] Tightness of drug regulation in the North
  • From: Khalil Elouardighi <gerrold@noos.fr>
• [e-drug] Re: Proposed Donation Legislation in the UK
  • From: "S. Hillstrom" <scott.hillstrom@manchestercompanies.com>
• [e-drug] Re: Study on tax subsidies for donations of expiring drugs
  • From: James Russo <JBRusso@aol.com>
• [e-drug] Contents of Prescrire International April 2002
  • From: Prescrire International <international@prescrire.org>
• [e-drug] Attendance to Open Session EDL WHO meeting
  • From: Carmen Perez <Carmen_PEREZ@msf.org>
• [e-drug] Re: WHO EDL Committee to consider 6 more antiretrovirals
  • From: Essential Drugs Project <edp@gn.apc.org>
• [e-drug] Re: Study on tax subsidies for donations of expiring drugs
  • From: Bonnie Fundafunda <bfunda@echohealth.org.uk>
• [e-drug] Generic drug pricing fraud in the UK?
  • From: Jon Harper <jrharper@axelero.hu>
• [e-drug] Study on tax subsidies for donations of expiring drugs
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] Re: Description/definition of essential drugs by WHO
  • From: Douglas Ball <dball@healthnet.zw>
• [e-drug] Re: description/definition of essential drugs
  • From: Murtada Sesay <msesay@unicef.org>
• [e-drug] Essential drug or essential medicine?
  • From: Beverley Snell <bev@burnet.edu.au>
April 10, 2002
• [e-drug] Botswana president backs ARV roll-out
  • From: e-drug@usa.healthnet.org
• [e-drug] Re: description/definition of essential drugs by WHO
  • From: Patrice Trouiller <PTrouiller@chu-grenoble.fr>
• [e-drug] What drugs could be removed from WHO Model EDL?
  • From: Richard Laing <richardl@bu.edu>
• [e-drug] Re: Essential drug or essential medicine?
  • From: Alistair Bolt <alistair.bolt@norfolk-norwich.thenhs.com>
• [e-drug] Essential drug or essential medicine?
  • From: B.Futter@ru.ac.za
• [e-drug] WHO model formulary
  • From: WilbertBannenberg@compuserve.com
• [e-drug] updating WHO EDL/EML
  • From: WilbertBannenberg@compuserve.com
• [e-drug] description/definition of essential drugs by WHO
  • From: WilbertBannenberg@compuserve.com
• [e-drug] Double or dubious standards for regulation and export?
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] Re: WHO EDL Committee to consider 6 more antiretrovirals
  • From: James Love <james.love@cptech.org>
April 09, 2002
• [e-drug] New HAI Europe report on advertising medicines
  • From: Lisa Hayes <Lisa@hai.antenna.nl>
• [e-drug] WHO EDL Committee to consider 6 more antiretrovirals
  • From: WilbertBannenberg@compuserve.com
• [e-drug] Re: Advertising and marketing of essential drugs
  • From: "Uzodinma A. Adirieje" <afrepton@hotmail.com>
• [e-drug] Annual Conference Pharmaceutical Society of Kenya
  • From: Mary Ojoo <mojoo@gerties.org>
April 07, 2002
• [e-drug] Re: Standardized Pill Imprint Codes USP
  • From: Bernhard Edgren <bernhard.edgren@pp.inet.fi>
• [e-drug] Re: Just how tainted has medicine become?
  • From: Tom Poe <tompoe@renonevada.net>
April 06, 2002
• [e-drug] Just how tainted has medicine become?
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] Re: Supply crisis of BMS ARVs in Kenya
  • From: Mary Ojoo <mojoo@gerties.org>
• [e-drug] Essential drugs model list by ATC
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] Standardized Pill Imprint Codes USP
  • From: Gordon Schiff <Gdschiff@aol.com>
• [e-drug] Re: DTC advertising
  • From: Peter R Mansfield <peter@healthyskepticism.org>
• [e-drug] Re: Advertising and marketing of essential drugs
  • From: Kibumba George <kibumba@yahoo.com>
• [e-drug] Re: Thalidomide supplier
  • From: Kirsten Myhr <kirsten.myhr@relis.ulleval.no>
• [e-drug] 2001 International Drug Price Indicator Guide
  • From: Julie McFadyen <jmcfadyen@msh.org>
• [e-drug] Re: DTC advertising
  • From: Barbara Mintzes <bmintzes@telus.net>
April 05, 2002
• [e-drug] Seminar on the Ethics of Research related to Healthcare in Developing Countries
  • From: Yvonne Melia <ymelia@nuffieldfoundation.org>
• [e-drug] Thalidomide supplie
  • From: "Leona Coetzer PPC" <Coetzl@comed.pwv.gov.za>
• [e-drug] Advertising in online journals (cont)
  • From: "Staffan Svensson" <staffan.svensson@pharm.gu.se>
• [e-drug] Global Fund overwhelmed by requests
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] HIV drug under review
  • From: E-drug <e-drug@usa.healthnet.org>
• [e-drug] Brain-drain of health professionals (cont)
  • From: "Billy Futter" <B.Futter@ru.ac.za>
• [e-drug] BMJ Ed: Murder by fake drugs
  • From: "Kirsten Myhr" <kirsten.myhr@relis.ulleval.no>
• [e-drug] Supply crisis of BMS ARVs in Kenya
  • From: daniel_berman@msf.org
April 04, 2002
• [e-drug] Brain-drain of health professionals (cont)
  • From: "Hillstrom, Scott" <Scott.Hillstrom@manchestercompanies.com>
• [e-drug] Advertising and marketing of essential drugs
  • From: Belinda Assam <belindassam@yahoo.com>
• [e-drug] Brain-drain of health professionals (cont)
  • From: msesay@unicef.org (MURTADA SESAY)
• [e-drug] Pakistan: Sales Tax on Medicines (cont)
  • From: Azhar Hussain <azhar@thenetwork.org.pk>
• [e-drug] DTC advertising
  • From: "Bella Brushin" <bbrushin@deakin.edu.au>
April 03, 2002
• [e-drug] Advertising in online journals (cont)
  • From: "Dr.L.Offerhaus" <lo@euronet.nl>
• [e-drug] Brain-drain of health professionals
  • From: "Avisha Neerahoo" <avisha-n@webmail.co.za>
April 02, 2002
• [e-drug] Adverse effects of mefloquine: due to primary liver damage?
  • From: andrew Herxheimer <Andrew_Herxheimer@compuserve.com>
• [e-drug] Advertising in online journals (cont)
  • From: "Staffan Svensson" <staffan.svensson@pharm.gu.se>
• [e-drug] Vitamin A and child deaths in India (cont)
  • From: "Kirsten Myhr" <kirsten.myhr@relis.ulleval.no>
April 01, 2002
• [e-drug] RFI counterfeit drugs (cont)
  • From: msesay@unicef.org (MURTADA SESAY)